Treatment outcomes for small cell carcinoma of the bladder: results from a UK patient retrospective cohort study
Lim, J. H.
Henderson, D. R.
AffiliationOncology, Queen Alexandra Hospital Portsmouth Oncology Centre, Portsmouth, UK; Department of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK
MetadataShow full item record
AbstractBackground: Small cell carcinoma of the bladder (SCCB) is rare, accounting for under 1% of all bladder carcinomas. It is aggressive and outcomes are poor due to early metastatic spread. Owing to its rarity, there are limitations on data to propose standardised management pathways. Patients and methods: We conducted a retrospective analysis of patients presenting with pure or predominant histology SCCB to 26 UK institutions between 2006 and 2016. Data cut-off date was 1/2/2018. We report on patient characteristics, treatment received and subsequent clinical outcomes. Results: 409 eligible patients were included. 306 (74.8%) were male, median age was 71 years (range 35-96) and 189 (46.2%) had pure histology SCCB. At data cut-off, 301 patients (73.6%) have died. Median overall survival (OS) was 15.9 (95% confidence interval (CI) 13.2-18.7) months. 200 patients (48.9%), were confirmed to have bladder confined disease (N0 M0), with a median OS of 28.3 (95% CI 20.9-35.8) months, versus 12.7 (95% CI 10.9-14.6) months for 172 (42.1%) patients with confirmed N1-3 and/or M1 disease (hazard ratio 2.03, 95% CI 1.58-2.60, p=<0.001). 247 patients (61.5%) received primary chemotherapy, with a median OS of 21.6 (95% CI 15.5-27.6) months, versus 9.1 (95% CI 5.4-12.8) months in those who did not (HR 0.46, 95%CI 0.37-0.59, p=<0.001). Choice of chemotherapy agent did not alter outcomes. For those with bladder confined disease, 61 patients (30.5%) had cystectomy and 104/200 (52.0%) had radiotherapy. Survival outcomes were similar despite choice of cystectomy or radiotherapy. Only 6 patients (1.5%) were identified to have brain metastases at any time point. Conclusions: This is the largest retrospective study of all stage SCCB to date. Patients have a poor prognosis overall but with improved survival in those able to receive chemotherapy and with organ confined disease. Brain metastases are rare.
CitationChau C, Rimmer Y, Choudhury A, Leaning D, Law A, Enting D, et al. Treatment outcomes for small cell carcinoma of the bladder: results from a UK patient retrospective cohort study. Int J Radiat Oncol Biol Phys. 2021.
JournalInternational Journal of Radiation Oncology Biology Physics
- Prognosis of early stage small cell bladder cancer is not always dismal.
- Authors: Lim JH, Sundar S
- Issue date: 2019
- Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients.
- Authors: Pasquier D, Barney B, Sundar S, Poortmans P, Villa S, Nasrallah H, Boujelbene N, Ghadjar P, Lassen-Ramshad Y, Senkus E, Oar A, Roelandts M, Amichetti M, Vees H, Zilli T, Ozsahin M
- Issue date: 2015 Jul 15
- Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study.
- Authors: Cattrini C, Cerbone L, Rubagotti A, Zinoli L, Latocca MM, Messina C, Zanardi E, Boccardo F
- Issue date: 2019 Aug
- Intravesical recurrence after bladder sparing treatment of small cell carcinoma of the bladder: Characteristics, treatment, and outcome.
- Authors: van de Kamp M, Meijer R, Pos F, Kerst M, van Werkhoven E, van Rhijn B, Horenblas S, Bex A
- Issue date: 2018 Jun
- Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.
- Authors: Sroussi M, Elaidi R, Fléchon A, Lorcet M, Borchiellini D, Tardy MP, Gravis G, Guérin M, Laguerre B, Estrade F, Delva R, Barthélémy P, Loriot Y, Lavaud P, Lebret T, Neuzillet Y, Penel N, Houede N, Pouessel D, Rousseau B, Mussat E, Gross-Goupil M, Culine S, Gauthier H, Gobert A, Roupret M, Huillard O, Tartas S, Radulescu C, Allory Y, Oudard S
- Issue date: 2020 Aug